Delivering mitochondrial health
Abliva would like to invite interested shareholders and investors to a fun and informal “Fireside Chat” with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Stockholm (28 September) and Lund (29 September). After a long stretch of stringent travel restrictions and two-dimensional zoom presentations, we would like to invite Abliva shareholders […]
Abliva will attend the digital/hybrid event: 21st Annual Biotech in Europe Forum (BEF), on 7 - 8 October 2021.
Italian patient organization Mitocon arranges this year's Mitochondrial Diseases Conference in virtual. Abliva's Chief Medical Officer, Magnus Hansson, will give a flash presentation and join round table discussions at the meeting.
Abliva will attend Aktiespararna's Kvinnokvällen Malmö, on 19 October 2021.. CEO Ellen Donnelly will be presenting the company at 7:30 p.m. CEST.
Abliva will attend the BioStock Life Science Summit 2021. CEO Ellen Donnelly will be presenting the company on 20 October at 2:00 p.m. CEST.
Abliva will attend the virtual conference Mitochondrial Medicine - Therapeutic Development, organized by the Wellcome Connecting Science located at the Wellcome Genome Campus in the UK, on 30 Nov - 2 Dec 2021. Abliva's CMO, Magnus Hansson, has been invited to give a presentation on the topic Academia-pharma interplay in drug development, during Session 1: Mitochondrial […]
Abliva will attend and present at the Mitochondria-Targeted Drug Development Summit in Boston, MA, USA. The event will be held on 22 - 24 February 2022. CEO Ellen Donnelly will be presenting in the session Patient-Focused Drug Development for Mitochondrial Disease. Synopsis: Highlighting the impact of patient input on research and development at Abliva Providing […]
Abliva invites to a conference call and an online presentation on June 1, 2022, at 14:00 CEST. Abliva's CEO Ellen Donnelly, CMO Magnus Hansson and CFO Catharina Johansson will inform about the financing and implementation of KL1333 Phase 2/3 study and answer questions. The presentation will be held in English. After the presentation, there will […]
Abliva will participate at the United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium in Phoenix, Arizona. Abliva's CMO, Magnus Hansson, will participate in a panel discussion on clinical trials together with Baylor College of Medicine, Cyclerion Therapeutics, and Khondrion, on Friday June 10.
In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about the path forward directly from Ellen Donnelly (CEO) and the Abliva team. We hope you will join us in Lund during the Midsummer week to […]
In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about the path forward directly from Ellen Donnelly (CEO) and the Abliva team. We hope you will join us in Stockholm during the Midsummer week to […]
On June 29-30, Abliva will participate at Bioblast 2022: Inaugural Conference of Bioenergetics Communications in Innsbruck, Austria. Abliva's Communications Officer & Lab Manager, Eleonor Åsander Frostner, will present a summary of the company's recent preprint publication "Towards a treatment for mitochondrial disease: current compounds in clinical development".
